Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Equity Capital Markets

<div class="content-highlight"><div>Over a 6-12 months view, we believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share. At a market cap of 11.5 trillion won for SK Bioscience, this would suggest a P/S multiple of 11.5x (30% discount to the average P/S multiple of its comps in 2022) assuming annual revenue of 1 trillion won for the company. </div></div><p><strong>Our base case value of 149,000 won per share would represent 129% higher than the high end IPO price of 65,000 won</strong>. Given such a high upside versus the IPO price, we have a <strong>POSITIVE</strong> view of this IPO.</p><p>Remember, the key investment merits of SK Bioscience is that it is a company which has been picked by AstraZeneca and NovaVax to produce COVID-19 vaccines and there is a good chance that other major global biopharm companies may select SK Bioscience for additional COVID-19 vaccines production.</p>

Over a 6-12 months view, we believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share. At a market cap of 11.5 trillion won for SK Bioscience, this would suggest a P/S multiple of 11.5x (30% discount to the average P/S multiple of its comps in 2022) assuming annual revenue of 1 trillion won for the company. Our base case value of 149,000 won per share would represent 129% higher than the high end IPO price of 65,000 won. Given such a high upside versus the IPO price, we have a POSITIVE view of this IPO.Remember, the key investment merits of SK Bioscience is that it is a company which has been picked by AstraZeneca and NovaVax to produce COVID-19 vaccines and there is a good chance that other major global biopharm companies may select SK Bioscience for additional COVID-19 vaccines production.

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

SK Biopharmaceuticals   / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/sk-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:393:1" rel="noopener">SK Holdings (034730 KS)</a> aims to raise US$1bn via selling 11% of <a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals Co Ltd (326030 KS)</a>.</p><p>The shares have more than tripled since listing and the IPO lock-up just expired last month.  While the discount appears tempting overall the stock doesn't score well on our framework.</p>

SK Holdings (034730 KS) aims to raise US$1bn via selling 11% of SK Biopharmaceuticals Co Ltd (326030 KS).The shares have more than tripled since listing and the IPO lock-up just expired last month.  While the discount appears tempting overall the stock doesn't score well on our framework.

SK Biopharma Placement - Juicy Discount but the Rest Looks Iffy

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

<p>The Korea Exchange (KRX) launched 5 indices last year following the New Deal initiative that the Government launched to digitalise social infrastructure and jumpstart the transition to green energy.</p><p>The KRX created 4 indices tracking the Secondary Battery, Biotech, Internet and Gaming sectors that are expected to benefit from the New Deal initiative plus an additional index (BBIG) that includes the top 3 stocks from each sector.</p><p>All indices have performed well since then. The KRX announced changes to the 5 indices late last week and the changes become effective post the close of trading on 25 February.</p><div><p><a href="https://www.smartkarma.com/entities/kakao-games-corp" target="_blank" data-smartkarma-citation="entities:26730:1" rel="noopener">Kakao Games Corp (293490 KS)</a> replaces <a href="https://www.smartkarma.com/entities/pearl-abyss-corp" target="_blank" data-smartkarma-citation="entities:24391:1" rel="noopener">Pearl Abyss (263750 KS)</a> in the BBIG Index.</p></div><div><p>In the Secondary Battery index, <a href="https://www.smartkarma.com/entities/soulbrain-co-ltd" target="_blank" data-smartkarma-citation="entities:16883:1" rel="noopener">Soulbrain (036830 KS)</a> and <a href="https://www.smartkarma.com/entities/l-f-co-ltd" target="_blank" data-smartkarma-citation="entities:14300:1" rel="noopener">L&amp;F Co Ltd (066970 KS)</a> replace <a href="https://www.smartkarma.com/entities/doosan-solus-co-ltd" target="_blank" data-smartkarma-citation="entities:28947:1" rel="noopener">Doosan Solus Co Ltd (336370 KS)</a> and <a href="https://www.smartkarma.com/entities/foosung-co-ltd" target="_blank" data-smartkarma-citation="entities:16811:1" rel="noopener">Foosung Co Ltd (093370 KS)</a>.</p></div><div><p>In the Biotech index, <a href="https://www.smartkarma.com/entities/shinpoong-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:7296:1" rel="noopener">Shinpoong Pharmaceutical (019170 KS)</a> and <a href="https://www.smartkarma.com/entities/green-cross-corp" target="_blank" data-smartkarma-citation="entities:2969:1" rel="noopener">Green Cross (006280 KS)</a> replace <a href="https://www.smartkarma.com/entities/alteogen-inc" target="_blank" data-smartkarma-citation="entities:15886:1" rel="noopener">Alteogen Inc (196170 KS)</a> and <a href="https://www.smartkarma.com/entities/hanmi-pharm-co-ltd" target="_blank" data-smartkarma-citation="entities:12476:1" rel="noopener">Hanmi Pharm (128940 KS)</a>.</p></div><div><p>In the Internet index, <a href="https://www.smartkarma.com/entities/ace-technologies-corp" target="_blank" data-smartkarma-citation="entities:7868:1" rel="noopener">Ace Technologies (088800 KS)</a> and <a href="https://www.smartkarma.com/entities/rsupport-co-ltd" target="_blank" data-smartkarma-citation="entities:14783:1" rel="noopener">Rsupport Co Ltd (131370 KS)</a> replace <a href="https://www.smartkarma.com/entities/kg-inicis-co-ltd" target="_blank" data-smartkarma-citation="entities:5234:1" rel="noopener">KG Inicis Co Ltd (035600 KS)</a> and <a href="https://www.smartkarma.com/entities/ubiquoss-inc" target="_blank" data-smartkarma-citation="entities:14341:1" rel="noopener">Ubiquoss Holding (078070 KS)</a>.</p></div><div><p>In the Gaming index, <a href="https://www.smartkarma.com/entities/kakao-games-corp" target="_blank" data-smartkarma-citation="entities:26730:1" rel="noopener">Kakao Games Corp (293490 KS)</a> and <a href="https://www.smartkarma.com/entities/neptune-company" target="_blank" data-smartkarma-citation="entities:28826:1" rel="noopener">Neptune Company (217270 KS)</a> replace <a href="https://www.smartkarma.com/entities/neowiz-games-corp" target="_blank" data-smartkarma-citation="entities:12425:1" rel="noopener">Neowiz Games (095660 KS)</a> and Golfzon (215000 KS).</p></div>

The Korea Exchange (KRX) launched 5 indices last year following the New Deal initiative that the Government launched to digitalise social infrastructure and jumpstart the transition to green energy.The KRX created 4 indices tracking the Secondary Battery, Biotech, Internet and Gaming sectors that are expected to benefit from the New Deal initiative plus an additional index (BBIG) that includes the top 3 stocks from each sector.All indices have performed well since then. The KRX announced changes to the 5 indices late last week and the changes become effective post the close of trading on 25 February.Kakao Games Corp (293490 KS) replaces Pearl Abyss (263750 KS) in the BBIG Index.In the Secondary Battery index, Soulbrain (036830 KS) and L&amp;F Co Ltd (066970 KS) replace Doosan Solus Co Ltd (336370 KS) and Foosung Co Ltd (093370 KS).In the Biotech index, Shinpoong Pharmaceutical (019170 KS) and Green Cross (006280 KS) replace Alteogen Inc (196170 KS) and Hanmi Pharm (128940 KS).In the Internet index, Ace Technologies (088800 KS) and Rsupport Co Ltd (131370 KS) replace KG Inicis Co Ltd (035600 KS) and Ubiquoss Holding (078070 KS).In the Gaming index, Kakao Games Corp (293490 KS) and Neptune Company (217270 KS) replace Neowiz Games (095660 KS) and Golfzon (215000 KS).

KRX BBIG K-NewDeal Index Rebalance: First Set of Changes Announced

<div>
<p>A group of shareholders plans to raise around US$200m via selling a 4.6% stake in <a href="https://www.smartkarma.com/entities/i-mab" target="_blank" data-smartkarma-citation="entities:28384:1" rel="noopener">I-Mab (IMAB US).</a></p>
<p>We have previously covered the IPO in:</p>
</div><div><ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/i-mab-pre-ipo-strong-management-and-investor-backing-with-differentiated-products" target="_blank" rel="noopener">I-Mab (天境生物) Pre-IPO: Strong management and investor backing with differentiated products</a></li>
<li><a href="https://www.smartkarma.com/insights/i-mab-ipo-everest-deal-a-valuation-booster" target="_blank" rel="noopener">I-Mab (天境生物) IPO: Everest Deal a Valuation Booster</a></li>
<li><a href="https://www.smartkarma.com/insights/i-mab-ipo-trading-tiny-float-and-undemanding-valuation" target="_blank" rel="noopener">I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation</a></li>
</ul></div><div><p>In this insight, we will talk about updates since then and run the deal through our ECM framework.</p></div>


A group of shareholders plans to raise around US$200m via selling a 4.6% stake in I-Mab (IMAB US).
We have previously covered the IPO in:

I-Mab (天境生物) Pre-IPO: Strong management and investor backing with differentiated products
I-Mab (天境生物) IPO: Everest Deal a Valuation Booster
I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation
In this insight, we will talk about updates since then and run the deal through our ECM framework.

I-Mab Placement - Heading in the Right Direction

<div class="content-highlight">
<p><strong>SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021.</strong> The IPO price range is from 49,000 won to 65,000 won. The IPO deal base size ranges from US$1.0 billion to US$1.3 billion. The expected market cap after the IPO ranges from 3.8 trillion won to 5.0 trillion won, according to the bankers's valuation. The book building for the institutional investors starts on 4 March 2021. The lead bankers on this IPO include NH Investment &amp; Securities, Korea Investment &amp; Securities, and Mirae Asset Daewoo Securities. </p>
<p>Institutional investors will be allocated about 55% of the deal and retail 25%, and the rest will go to an employee stock ownership plan. There is a voluntary lock-up of 15 days to six months for investors. SK Bioscience is currently 98% owned by <a href="https://www.smartkarma.com/entities/sk-chemicals-co-ltd-new" target="_blank" data-smartkarma-citation="entities:26190:1" rel="noopener">Sk Chemicals Co Ltd/New (285130 KS) </a>and the latter company is 33.5% owned by <a href="https://www.smartkarma.com/entities/sk-discovery-co-ltd" target="_blank" data-smartkarma-citation="entities:5181:1" rel="noopener">Sk Discovery (006120 KS)</a>. </p>
<p>SK Bioscience was spun off from <a href="https://www.smartkarma.com/entities/sk-chemicals-co-ltd-new" target="_blank" data-smartkarma-citation="entities:26190:1" rel="noopener">Sk Chemicals Co Ltd/New (285130 KS)</a> in July 2018. SK Biosciene specializes in making vaccines. SK Bioscience is backed by <strong>Bill Gates.</strong> In June 2020, Bill Gates mentioned that SK Bioscience may be capable of producing 200 million COVID-19 vaccine kits by June 2021. The Bill &amp; Melinda Gates foundation <a href="https://www.skchemicals.com/prcenter/new_view.do" target="_blank" rel="noopener">gave</a> $3.6 million in May to SK Bioscience to accelerate the development of Covid-19 vaccines. </p>
</div>


SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The IPO price range is from 49,000 won to 65,000 won. The IPO deal base size ranges from US$1.0 billion to US$1.3 billion. The expected market cap after the IPO ranges from 3.8 trillion won to 5.0 trillion won, according to the bankers's valuation. The book building for the institutional investors starts on 4 March 2021. The lead bankers on this IPO include NH Investment &amp; Securities, Korea Investment &amp; Securities, and Mirae Asset Daewoo Securities. 
Institutional investors will be allocated about 55% of the deal and retail 25%, and the rest will go to an employee stock ownership plan. There is a voluntary lock-up of 15 days to six months for investors. SK Bioscience is currently 98% owned by Sk Chemicals Co Ltd/New (285130 KS) and the latter company is 33.5% owned by Sk Discovery (006120 KS). 
SK Bioscience was spun off from Sk Chemicals Co Ltd/New (285130 KS) in July 2018. SK Biosciene specializes in making vaccines. SK Bioscience is backed by Bill Gates. In June 2020, Bill Gates mentioned that SK Bioscience may be capable of producing 200 million COVID-19 vaccine kits by June 2021. The Bill &amp; Melinda Gates foundation gave $3.6 million in May to SK Bioscience to accelerate the development of Covid-19 vaccines. 


SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

South Korea

Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Samsung Biologics (207940 KS)

SK Bioscience IPO - Valuation Analysis

We believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share which would represent 129% higher than...

Douglas Kim

SK Biopharma Placement - Juicy Discount but the Rest Looks Iffy

SK Holdings (034730 KS) aims to raise US$1bn via selling 11% of SK Biopharmaceuticals Co Ltd (326030 KS). The shares have more than tripled since...

Sumeet Singh

KRX BBIG K-NewDeal Index Rebalance: First Set of Changes Announced

The KRX has announced changes to the KRX New Deal indices that will be effective after the close of trading on 25 February. Pearl Abyss is...

Brian Freitas

I-Mab Placement - Heading in the Right Direction

A group of shareholders plans to raise around US$200m via selling a 4.6% stake in I-Mab (IMAB US). We have previously covered the IPO as well.

Sumeet Singh

SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)